- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00756860
A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)
May 31, 2012 updated by: Amgen Research (Munich) GmbH
A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®) on Phosphate Binding in Healthy Volunteers
The purpose of this study is to determine if subjects on 2g AMG 223 will achieve 60% or greater reduction in urinary phosphorus from baseline compared to subjects on 2g Renagel®.
Renagel®, Sevelamer HCl is currently the market leader for the treatment of hyperphosphatemia in patients on dialysis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
66
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy non-smoking men and women between the ages of 18 and 45 years, inclusive the time of consent. Healthy is defined as an absence of clinically relevant abnormalities, as identified by a detailed medical history, complete physical examination, vital signs, 12 lead ECG, and clinical laboratory tests at Screening through randomization Females of child-bearing potential must be non-lactating, must have a negative serum pregnancy test before study enrollment, and must use a highly effective form of contraception for at least 3 months before study drug administration, during the study, and for an additional 1 month after study completion
- Male participants and/or their partners must use a highly effective form of contraception during sexual intercourse during the study and for an additional 1 month after study completion
- A body mass index (BMI) between 18 and 30 kg/m2, inclusive
- Serum phosphate within normal range
- Willing and able to provide written informed consent
- Willing and able to be confined to the clinical research unit (CRU) as required by the protocol
- Must abstain from any caffeine or alcohol within 72 hours of Day-7 through Day 7 inclusive.
Exclusion Criteria:
- Evidence or history of clinically significant hematologic, renal, endocrinologic, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing) judged to be relevant by the investigator
- History of bowel obstruction, dysphagia, swallowing disorders, gastrointestinal disorders such as inflammatory bowel disease, constipation, major gastrointestinal surgery, hemorrhoids, or gastric/duodenal ulcers
- Unable or unwilling to swallow numerous capsules/tablets
- Known hypersensitivity to Renagel® or its constituents
- Having an estimated glomerular filtration rate (GFR) < 80 ml/ min (Cockcroft Gault equation)
- Blood donation > 500 mL within 60 days of Screening
- History of alcohol abuse (more than 14 alcoholic drinks per week for men and 7 alcoholic drinks per week for women (one drink equals 12 oz beer, 8 oz of wine, or a drink containing one ounce of liquor) or use of illicit drugs within 12 months of Screening
- Positive results for the following tests:
- Urine drug and breath alcohol at Screening or Day -7,
- Serum pregnancy test (females only) at Screening or Day -7,
- Human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HepCAb) at Screening
- Women who are pregnant, breastfeeding, or plan to become pregnant during the course of the study Participation in another clinical trial with any investigational drug or device within 30 days or 5 half lives of the investigational drug (if known), whichever is longer, of study drug administration
- Use of prescription and nonprescription drugs (herbal remedies, vitamins, and nutraceuticals) within 14 days or 5 half-lives, whichever is longer, before Day -7 and during the study (excluding acetaminophen at doses of 2 g/day and hormonal birth control pills)
- Use of prescription and nonprescription drugs that may affect gut motility within 14 days or 5 half-lives, whichever is longer, before Day -7 and during the study
- Subject will not be available for follow-up assessment or concerns for subject's compliance with the protocol procedures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 2
30 subjects will be randomized on Day -1
|
2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
|
EXPERIMENTAL: 1
30 subjects will be randomized on Day -1
|
2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To compare the effects of 2g AMG 223 and 2g Renagel® on 24 hour urinary phosphorous excretion after multiple doses in healthy volunteers.
Time Frame: Including the 28-day Screening period, the 15-day residency period, and the follow-up on Day 15 (one week after discharge from the clinical research unit), the maximum subject participation is approximately 50 days.
|
Including the 28-day Screening period, the 15-day residency period, and the follow-up on Day 15 (one week after discharge from the clinical research unit), the maximum subject participation is approximately 50 days.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To compare the effects of 2g AMG 223 and 2g Renagel® on 24 hour fecal phosphorous excretion after multiple doses in healthy volunteers.
Time Frame: Including the 28-day Screening period, the 15-day residency period, and the follow-up on Day 15 (one week after discharge from the clinical research unit), the maximum subject participation is approximately 50 days.
|
Including the 28-day Screening period, the 15-day residency period, and the follow-up on Day 15 (one week after discharge from the clinical research unit), the maximum subject participation is approximately 50 days.
|
To assess safety and tolerability of multiple doses of 2g AMG 223 in healthy volunteers.
Time Frame: Including the 28-day Screening period, the 15-day residency period, and the follow-up on Day 15 (one week after discharge from the clinical research unit), the maximum subject participation is approximately 50 days.
|
Including the 28-day Screening period, the 15-day residency period, and the follow-up on Day 15 (one week after discharge from the clinical research unit), the maximum subject participation is approximately 50 days.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2008
Primary Completion (ACTUAL)
August 1, 2008
Study Completion (ACTUAL)
September 1, 2009
Study Registration Dates
First Submitted
September 11, 2008
First Submitted That Met QC Criteria
September 18, 2008
First Posted (ESTIMATE)
September 22, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
June 4, 2012
Last Update Submitted That Met QC Criteria
May 31, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20070885
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Renagel® (sevelamer hydrochloride)
-
Genzyme, a Sanofi CompanyCompletedChronic Kidney DiseaseUnited Kingdom
-
Genzyme, a Sanofi CompanyCompletedKidney Diseases | End-Stage Renal Disease | Chronic Renal InsufficiencyUnited States
-
Ineos Healthcare LimitedTerminatedChronic Kidney FailureUnited States, Italy, Brazil, Belgium, United Kingdom, Estonia, Bulgaria, Serbia, Israel, Czech Republic, Hungary, Lithuania, Mexico, Slovakia, South Africa
-
Astellas Pharma IncCompletedRenal Insufficiency | Chronic Kidney Disease | Renal DialysisJapan
-
The University of Hong KongCompleted
-
Medical University of LodzShireCompleted
-
Genzyme, a Sanofi CompanyCompletedPeritoneal Dialysis | Chronic Kidney DiseaseBelgium, United Kingdom, Denmark, France, Italy, Netherlands, Spain
-
Ineos Healthcare LimitedCompletedChronic Kidney FailureUnited Kingdom
-
Genzyme, a Sanofi CompanyCompletedChronic Kidney DiseaseUnited States
-
Tel-Aviv Sourasky Medical CenterGenzyme, a Sanofi Company; Wolfson Medical CenterCompletedHemodialysis | End Stage Renal Disease | Intimal Media ThicknessIsrael